latrepirdine has been researched along with Degenerative Diseases, Central Nervous System in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hawker, DD; Jansen Labby, K; Mataka, JJ; Silverman, RB; Trippier, PC | 1 |
| Bates, KA; Bharadwaj, PR; Gandy, S; Groth, D; Martins, RN; Perry, G; Porter, T; Steele, JW; Teimouri, E; Verdile, G | 1 |
| Cano-Cuenca, N; Jordán, J; Solís-García del Pozo, J | 1 |
| Bachurin, S; Shevtsova, E; Ustyugov, A | 1 |
| Aliev, G; Ashraf, GM; Bachurin, SO; Shevtsova, E; Tarasov, VV; Ustyugov, A | 1 |
| Bachurin, SO; Buchman, VL; Khritankova, IV; Kokhan, VS; Ninkina, NN; Peters, O; Shelkovnikova, TA; Ustyugov, AA | 1 |
| Bachurin, SO; Kireeva, EG; Shevtsova, EF | 1 |
5 review(s) available for latrepirdine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; Drug Design; Humans; Huntington Disease; Neurodegenerative Diseases; Nitric Oxide Synthase Type I; Oxidative Stress; Parkinson Disease; Protein Folding; Protein Structure, Quaternary; Proteostasis Deficiencies; Receptors, N-Methyl-D-Aspartate | 2013 |
Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Cognition; Humans; Huntington Disease; Indoles; Neurodegenerative Diseases; Neuroprotective Agents; Nootropic Agents | 2013 |
[Latrepirdine: a systematic review of the preclinical studies].
Topics: Animals; Biological Availability; Calcium Signaling; Cholinesterase Inhibitors; Disease Models, Animal; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Humans; Indoles; Mice; Mitochondria; Molecular Structure; Motor Neurons; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Protein Aggregation, Pathological; Rabbits; Rats; Receptors, N-Methyl-D-Aspartate; Tissue Distribution | 2015 |
Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).
Topics: Animals; Autophagy; DNA-Binding Proteins; Excitatory Amino Acid Antagonists; Female; Humans; Indoles; Mice; Mutation; Nerve Tissue Proteins; Neurodegenerative Diseases; Neuroprotective Agents; Protein Aggregation, Pathological; Recombinant Fusion Proteins; RNA-Binding Protein FUS | 2015 |
New Therapeutic Property of Dimebon as a Neuroprotective Agent.
Topics: Animals; Autophagy; Humans; Indoles; Mitochondria; Neurodegenerative Diseases; Neuroprotective Agents; RNA-Binding Protein FUS; tau Proteins | 2018 |
2 other study(ies) available for latrepirdine and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Dimebon reduces the levels of aggregated amyloidogenic protein forms in detergent-insoluble fractions in vivo.
Topics: Amyloidogenic Proteins; Animals; Detergents; gamma-Synuclein; Gene Expression; Indoles; Male; Mice; Mice, Transgenic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Spinal Cord; Ubiquitin; Ubiquitinated Proteins | 2012 |
[Mitochondria as the target for neuroprotectors].
Topics: Animals; Antiparkinson Agents; Brain; Cell Death; Cells, Cultured; Dopamine Agents; Ginkgo biloba; Indoles; Intracellular Membranes; Ion Channels; Lipid Peroxidation; Memantine; Mitochondria; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Neurodegenerative Diseases; Neuroprotective Agents; Neurotoxins; Nootropic Agents; Permeability; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Tacrine | 2005 |